{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:16:18Z","timestamp":1793812578292,"version":"4.6.1"},"reference-count":36,"publisher":"Becaris Publishing Limited","issue":"3","funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We investigated the effect of ataluren plus standard of care (SoC) on age at loss of ambulation (LoA) and respiratory decline in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) versus patients with DMD on SoC alone.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            Study 019 was a long-term Phase III study of ataluren safety in nmDMD patients with a history of ataluren exposure. Propensity score matching identified Study 019 and CINRG DNHS patients similar in disease progression predictors.\n            <jats:bold>Results &amp; conclusion:<\/jats:bold>\n            Ataluren plus SoC was associated with a 2.2-year delay in age at LoA (p\u00a0=\u00a00.0006), and a 3.0-year delay in decline of predicted forced vital capacity to &lt;60% in nonambulatory patients (p\u00a0=\u00a00.0004), versus SoC. Ataluren plus SoC delays disease progression and benefits ambulatory and nonambulatory patients with nmDMD.\n            <jats:bold>ClinicalTrials.gov registration<\/jats:bold>\n            :\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01557400\">NCT01557400<\/jats:ext-link>\n            .\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0196","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T13:25:03Z","timestamp":1637241903000},"page":"139-155","source":"Crossref","is-referenced-by-count":56,"title":["Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-3220","authenticated-orcid":false,"given":"Craig M","family":"McDonald","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California Davis School of Medicine, Davis, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[{"name":"Dubowitz Neuromuscular Centre &amp; MRC Centre for Neuromuscular Diseases, University College London, Institute of Child Health &amp; Great Ormond Street Hospital for Children Foundation Trust, London, UK"},{"name":"NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, Great Ormond Street Hospital Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Penematsa","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Jiang","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Kristensen","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bibbiani","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Goodwin","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-5427","authenticated-orcid":false,"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine, Children's National Health System &amp; the George Washington, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Morgenroth","sequence":"additional","affiliation":[{"name":"Therapeutic Research in Neuromuscular Disorders Solutions, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Werner","sequence":"additional","affiliation":[{"name":"PTC Therapeutics Germany GmbH, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Li","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Able","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiota","family":"Trifillis","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, South Plainfield, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1r","family":"Tulinius","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gothenburg University, Queen Silvia Children's Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JK","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Pereon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Voit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gidaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Schara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JB","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GP","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Vilchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tulinius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sejersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bushby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby K","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9(1), 77\u201393 (2010a).","journal-title":"Lancet Neurol."},{"issue":"8","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.nmd.2013.05.008","article-title":"195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14\u201316th December, 2012, Naarden, The Netherlands","volume":"23","author":"Ellis JA","year":"2013","unstructured":"Ellis JA, Vroom E, Muntoni F. 195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14\u201316th December, 2012, Naarden, The Netherlands. Neuromusc. Disord. 23(8), 682\u2013689 (2013).","journal-title":"Neuromusc. Disord."},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan D","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers 7(1), 13 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder S","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J. Rare Dis. 12(1), 79 (2017).","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"35","author":"Landfeldt E","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmuller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur. J. Epidemiol. 35(7), 643\u2013653 (2020).","journal-title":"Eur. J. Epidemiol."},{"issue":"2","key":"e_1_3_8_8_2","first-page":"121","article-title":"Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano L","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 31(2), 121\u2013125 (2012).","journal-title":"Acta Myol."},{"issue":"2","key":"e_1_3_8_9_2","first-page":"117","article-title":"Survival in Duchenne muscular dystrophy","volume":"31","author":"Rall S","year":"2012","unstructured":"Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta Myol. 31(2), 117\u2013120 (2012).","journal-title":"Acta Myol."},{"issue":"5","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2524.2010.00930.x","article-title":"The effect of caregiving on women in families with Duchenne\/Becker muscular dystrophy","volume":"18","author":"Kenneson A","year":"2010","unstructured":"Kenneson A, Bobo JK. The effect of caregiving on women in families with Duchenne\/Becker muscular dystrophy. Health Social Care Commun. 18(5), 520\u2013528 (2010).","journal-title":"Health Social Care Commun."},{"issue":"2","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","article-title":"Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials","volume":"16","author":"Humbertclaude V","year":"2012","unstructured":"Humbertclaude V, Hamroun D, Bezzou K Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur. J. Paediatr. Neurol. 16(2), 149\u2013160 (2012).","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"4","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 17(4), 347\u2013361 (2018).","journal-title":"Lancet Neurol."},{"issue":"2","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby K","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9(2), 177\u2013189 (2010).","journal-title":"Lancet Neurol."},{"issue":"11","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids","volume":"28","author":"McDonald CM","year":"2018","unstructured":"McDonald CM, Gordish-Dressman H, Henricson EK Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids. Neuromusc. Disord. 28(11), 897\u2013909 (2018).","journal-title":"Neuromusc. Disord."},{"issue":"12","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1164\/ajrccm.164.12.2103052","article-title":"Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy","volume":"164","author":"Phillips MF","year":"2001","unstructured":"Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am. J. Respir. Crit. Care Med. 164(12), 2191\u20132194 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen CL","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36(4), 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2147\/NDT.S93873","article-title":"Current and emerging treatment strategies for Duchenne muscular dystrophy","volume":"12","author":"Mah JK","year":"2016","unstructured":"Mah JK. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr. Dis. Treat. 12, 1795\u20131807 (2016).","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"e_1_3_8_18_2","first-page":"1223","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao QQ","year":"2015","unstructured":"Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Comp. Physiol. 5(3), 1223\u20131239 (2015).","journal-title":"Comp. Physiol."},{"key":"e_1_3_8_19_2","unstructured":"PTC Therapeutics International Ltd. Summary of product characteristics Translarna. European Medicines Agency 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/translarna-epar-product-information_en.pdf (2020)."},{"issue":"7140","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch EM","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J PTC124 targets genetic disorders caused by nonsense mutations. Nature 447(7140), 87\u201391 (2007).","journal-title":"Nature"},{"issue":"4","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby K","year":"2014","unstructured":"Bushby K, Finkel R, Wong B Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4), 477\u2013487 (2014).","journal-title":"Muscle Nerve"},{"issue":"10101","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald CM","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10101), 1489\u20131498 (2017a).","journal-title":"Lancet"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0095"},{"issue":"2","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"e1921306","DOI":"10.1001\/jamanetworkopen.2019.21306","article-title":"Assessment of treatment effect with multiple outcomes in 2 clinical trials of patients with duchenne muscular dystrophy","volume":"3","author":"Li D","year":"2020","unstructured":"Li D, McDonald CM, Elfring GL Assessment of treatment effect with multiple outcomes in 2 clinical trials of patients with duchenne muscular dystrophy. JAMA Netw. Open 3(2), e1921306 (2020).","journal-title":"JAMA Netw. Open"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0171"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0086"},{"issue":"3","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 17(3), 251\u2013267 (2018).","journal-title":"Lancet Neurol."},{"issue":"5","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant DJ","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 17(5), 445\u2013455 (2018).","journal-title":"Lancet Neurol."},{"issue":"1","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","article-title":"The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures","volume":"48","author":"Henricson EK","year":"2013","unstructured":"Henricson EK, Abresch RT, Cnaan A The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48(1), 55\u201367 (2013).","journal-title":"Muscle Nerve"},{"issue":"10119","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald CM","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391(10119), 451\u2013461 (2018).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used","volume":"48","author":"McDonald CM","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48(1), 32\u201354 (2013).","journal-title":"Muscle Nerve"},{"issue":"8","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1007\/s11999-015-4239-4","article-title":"Statistics in brief: an introduction to the use of propensity scores","volume":"473","author":"Inacio MC","year":"2015","unstructured":"Inacio MC, Chen Y, Paxton EW, Namba RS, Kurtz SM, Cafri G. Statistics in brief: an introduction to the use of propensity scores. Clin. Orthop. Relat. Res. 473(8), 2722\u20132726 (2015).","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"1","key":"e_1_3_8_33_2","first-page":"5","article-title":"Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet","volume":"9","author":"Ciafaloni E","year":"2016","unstructured":"Ciafaloni E, Kumar A, Liu K Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet. J. Pediatr. Rehab. Med. 9(1), 5\u201311 (2016).","journal-title":"J. Pediatr. Rehab. Med."},{"issue":"6","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti V","year":"2013","unstructured":"Ricotti V, Ridout DA, Scott E Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psych. 84(6), 698\u2013705 (2013).","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"e_1_3_8_35_2","first-page":"185","article-title":"Local and global optimal propensity score matching","author":"Coca-Perraillon M","year":"2007","unstructured":"Coca-Perraillon M. Local and global optimal propensity score matching. SAS Global Forum 185 (2007). https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/forum2007\/185-2007.pdf","journal-title":"SAS Global Forum"},{"issue":"12","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase IIa study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel RS","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B Phase IIa study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE 8(12), e81302 (2013).","journal-title":"PLoS ONE"},{"issue":"4","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","article-title":"Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study","volume":"158","author":"Trucco F","year":"2020","unstructured":"Trucco F, Domingos JP, Tay CG Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study. Chest 158(4), 1606\u20131616 (2020).","journal-title":"Chest"},{"issue":"5","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"Peay HL","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin. Ttherapeut. 36(5), 624\u2013637 (2014b).","journal-title":"Clin. Ttherapeut."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2021-0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T14:57:29Z","timestamp":1676645849000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.2217\/cer-2021-0196"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0196","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}